Conduit Pharmaceuticals

What Conduit Pharmaceuticals does

Conduit Pharmaceuticals, now operating as CDT Equity Inc. (NASDAQ: CDT), is a clinical-stage biopharmaceutical development company headquartered in San Diego, California, that focuses on identifying, enhancing, and advancing therapeutic assets through AI-driven drug repurposing, solid-form chemistry, and asset repositioning. Its proprietary portfolio comprises three named candidates—AZD1656, AZD5904, and CDT1656—each developed via AI-assisted workflows spanning repurposing, discovery acceleration, solid-form identification, and clinical trial monitoring. The company was originally established in 2019 and has since evolved from a single-purpose biotech into a broader platform branded as CDT Equity Inc.

The company's technology stack rests on a strategic collaboration with Sarborg Limited, initiated in December 2024, which supplies the AI and cybernetics tooling used across the development pipeline. The first phase of that collaboration was reported complete in late January 2025. The company operates with a lean team of 1-10 employees and is pre-commercial, with no disclosed revenue or product pricing. Its stated go-to-market model is not direct drug sales but rather the creation of shareholder value through licensing arrangements and strategic M&A, positioning the firm as a platform for transformative innovation rather than a vertically integrated pharmaceutical manufacturer. Investor relations are handled through a corporate website, SEC filings, email alerts, and standard social media channels.

Capital formation to date is modest, with a single recorded funding event of $1.7 million in February 2025. The company is incorporated in the United States and trades publicly on NASDAQ. The only named executive is Chief Scientific Officer Joanne Holland, and no AI/ML leadership, board composition, or operational headcount is publicly detailed in the available data, which materially constrains due-diligence visibility into execution capacity.

Name

Conduit Pharmaceuticals

Legal name

CDT Equity Inc.

Website

https://conduitpharma.com

Company type

Public

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

Conduit Pharmaceuticals (CDT Equity Inc., NASDAQ: CDT) is a clinical-stage biopharmaceutical development company using AI-driven drug repurposing and solid-form chemistry to advance proprietary therapeutic assets. The pre-commercial, San Diego-based firm targets shareholder value through licensing and strategic M&A.

Ownership category

akta.pro rank

Product category

Clinical-Stage Biopharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)

akta.pro secondary industry

Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)

Keywords

• Clinical-stage biopharmaceutical
• Drug repurposing platform
• AI-driven drug development
• Therapeutic asset repositioning
• Solid-form chemistry

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Distribution channels1 record

Marketing channels3 records

Core offering

Conduit Pharmaceuticals (operating as CDT Equity Inc.) is a clinical-stage biopharmaceutical development company that identifies, enhances, and advances high-potential therapeutic assets using AI-driven drug repurposing, solid-form chemistry, and asset repositioning. Its proprietary pipeline includes three therapeutic assets—AZD1656, AZD5904, and CDT1656. The company plans to create shareholder value through licensing arrangements, strategic M&A, and positioning itself as a platform for transformative therapeutic innovation.

Product overview

Conduit Pharmaceuticals, now operating as CDT Equity Inc. (NASDAQ: CDT), is a data-driven biopharmaceutical development company that operates as a unified platform for identifying, enhancing, and advancing high-potential therapeutic assets. The company leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. Its proprietary portfolio includes three named therapeutic assets—AZD1656, AZD5904, and CDT1656—all developed through AI-driven processes for drug repurposing, discovery acceleration, solid-form identification, and clinical trial optimization.

Differentiator

Problem solved

Functional benefit

Products and services

• AZD1656
• AZD5904
• CDT1656

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Sarborg LimitedcoreTechnology or Integration · 1 December 2024Strategic collaboration initiated in December 2024 to integrate AI and cybernetics into Conduit Pharmaceuticals' drug development operations. The partnership aims to streamline drug repurposing, accelerate discovery, optimize solid-form identification, and enhance clinical trial monitoring. Conduit expects AI-driven processes to shorten development timelines, reduce costs, and improve predictability of outcomes for its proprietary assets including AZD1656, AZD5904, and CDT1656. First phase of collaboration was completed in January 2025.

Recent moves3 records

Expansion highlights3 records

Direct peers

• Roivant Sciences: Roivant operates a 'Vant' platform model that in-licenses and reposition deprioritized pharmaceutical assets from larger pharma — the same asset-repositioning strategy Conduit describes with its AZD-licensed assets. Roivant directly competes with Conduit for sourcing, development, and licensing economics of small-molecule programs.
• Recursion Pharmaceuticals: Recursion is an AI-driven drug discovery company using machine learning and high-throughput experimentation to develop novel therapeutics. It directly parallels Conduit's positioning as a data-driven biotech using AI to compress timelines and identify new opportunities across its pipeline.
• Schrödinger, Inc. Schrödinger applies computational chemistry, physics-based simulation, and machine learning to small-molecule drug discovery and materials science. It is the most established computational-discovery peer and serves as a direct comparator for Conduit's AI + solid-form chemistry positioning.
• PureTech Health: PureTech develops and partners on a portfolio of clinical-stage therapeutic programs derived from applied research. Its model of advancing multiple programs toward licensing and M&A mirrors Conduit's stated platform strategy of in-licensing, repurposing, and out-licensing assets.

Emerging players

• Insitro: Insitro uses machine learning and high-throughput biology to discover and develop therapeutics, with overlap to Conduit's AI-driven methodology. It is at a more advanced stage of platform development but shares the same technology thesis.
• Cortexyme: Cortexyme was a clinical-stage biotech that repositioned an existing small molecule (atuzaginstat) into an indication-driven program. It is similar in scale and stage to Conduit and provides a benchmark for repurposed-asset clinical outcomes.
• Lantern Pharma: Lantern Pharma is an AI-driven oncology-focused clinical-stage biotech using a computational platform (RADR) to identify and develop therapeutic candidates, including repositioned molecules. Directly comparable as a small public AI-biotech with a similar multi-asset strategy.
• BioXcel Therapeutics: BioXcel applies AI to drug repurposing and repositioning, particularly in immunology and neuroscience. Its strategy of leveraging AI to identify new indications for existing drugs is one of the closest direct analogues to Conduit's stated methodology.

Broad incumbents

• BridgeBio Pharma: BridgeBio is a clinical-stage biotech that in-licenses and develops assets targeting genetic diseases and rare conditions across multiple programs. As a more established clinical-stage operator with a similar multi-asset model, it functions as an incumbent comp for Conduit's clinical path and licensing economics.

Others

• AstraZeneca: AstraZeneca is the originator of the AZD1656 and AZD5904 assets now being advanced by Conduit. As the source of those programs, AZ is the upstream licensor and a logical potential partner or acquirer; it also broadly operates in the same small-molecule therapeutic space Conduit's assets address.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Conduit Pharmaceuticals